anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Anifrolumab was progressed to clinical development for SLE and for scleroderma. First approval was granted by the FDA in August 2021, for the indication of moderate to severe systemic lupus erythematosus (SLE) in patients who are receiving standard therapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IFNα appears to enhance the maturation or activation of dendritic cells (DCs) [6-10], and increased expression of type I interferons has been described in several autoimmune diseases including SLE [1-2,5,11] and insulin-dependent diabetes mellitus (IDDM) [4]. Pharmaceutical intervention options to combat elevated IFNα levels include neutralising circulating IFNα (as achieved by sifalimumab) or blocking/competitively inhibiting IFNα binding to its cognate receptor. The latter is the mechanism by which anifrolumab acts.